Goldman Sachs’s Exagen XGN Stock Holding History

Goldman Sachs’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$242K	Sell	52,082 -69,352	-57%	-$261K	﹤0.01%	6112
2026 Q1	$364K	Buy	121,434 +39,810	+49%	+$154K	﹤0.01%	5784
2025 Q4	$496K	Buy	81,624 +19,805	+32%	+$180K	﹤0.01%	5596
2025 Q3	$679K	Buy	61,819 +39,217	+174%	+$347K	﹤0.01%	5314
2025 Q2	$158K	Buy	+22,602	New	+$137K	﹤0.01%	5722
2022 Q1	–	Sell	-10,738	Closed	-$125K	–	6942
2021 Q4	$125K	Buy	10,738 +105	+1%	+$1.23K	﹤0.01%	6075
2021 Q3	$145K	Buy	10,633 +444	+4%	+$5.9K	﹤0.01%	5832
2021 Q2	$153K	Buy	+10,189	New	+$156K	﹤0.01%	5845
2020 Q3	–	Sell	-191,978	Closed	-$2.38M	–	5563
2020 Q2	$2.38M	Buy	+191,978	New	+$2.6M	﹤0.01%	3328
2019 Q4	–	Sell	-18,000	Closed	-$279K	–	5431
2019 Q3	$279K	Buy	+18,000	New	+$291K	﹤0.01%	4712

Other funds holding XGN

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Goldman Sachs's XGN Position: Q2 2026 in Review

Goldman Sachs reduced its Exagen (XGN) stake by 57% in Q2 2026, selling an estimated $261K and leaving 52,082 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #6112.

Goldman Sachs first reported a position in XGN in Q3 2019 and has held it in 10 quarters since. The position peaked at $2.38M in Q2 2020. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

Goldman Sachs held 52,082 shares of Exagen worth $242K as of Q2 2026.
Goldman Sachs sold 69,352 Exagen shares in Q2 2026, an estimated $261K.
Exagen made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6112 holding.
Goldman Sachs first reported a position in Exagen in Q3 2019 and has held it in 10 quarters since.
Goldman Sachs's Exagen position peaked at $2.38M in Q2 2020.
57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.